Division of Hematology-Oncology, Department of Medicine, Northwell Health, Manhasset, New York, USA.
Northwell Cancer Institute, Hematology/Medical Oncology, Monter Cancer Center, Lake Success, New York, USA.
BMJ Case Rep. 2020 Sep 14;13(9):e236073. doi: 10.1136/bcr-2020-236073.
Recent studies have shown that BRAF inhibitors, such as vemurafenib, are effective in inducing long periods of remission in relapsed hairy cell leukaemia. Acute pancreatitis is one of the rare complications that is reported with vemurafenib use. As severe pancreatitis can be life threatening, physicians should be vigilant of this side effect and promptly treat patients that develop clinical signs and symptoms while receiving vemurafenib. We present an interesting case of vemurafenib-induced pancreatitis that not only resolved but also did not recur after reintroduction of the drug at a reduced dose.
最近的研究表明，BRAF 抑制剂，如 vemurafenib，可有效诱导复发性毛细胞白血病的长时间缓解。胰腺炎是 vemurafenib 使用过程中报告的罕见并发症之一。由于重症胰腺炎可能危及生命，因此医生应该警惕这种副作用，并在接受 vemurafenib 治疗的患者出现临床症状和体征时及时治疗。我们报告了一例有趣的 vemurafenib 诱导的胰腺炎病例，该病例不仅得到了缓解，而且在降低剂量重新使用该药后也没有复发。
